FULL-LENGTH ARTICLE

Translational Research

Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease

Seth D. Reighard^{1,2,3}, Durga Krishnamurthy¹, Hilal Cevik^{1,4}, David E. Ochayon¹, Ayad Ali^{1,2,3}, Harsha Seelamneni¹, Hermine I. Brunner^{5,6}, Stephen N. Waggoner^{1,2,3,4,5,*}

¹ Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

² Medical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

³ Immunology Graduate Training Program, Cincinnati, Ohio, USA

⁴ Molecular and Developmental Biology Graduate Program, Cincinnati, Ohio, USA

⁵ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

⁶ Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

ARTICLE INFO

Article History:

Received 21 October 2019

Accepted 6 September 2020

Key Words:

CD8 T cell

IL-15

IL-2

natural killer

systemic lupus erythematosus

therapy

ABSTRACT

Background aims: Certain therapies (e.g., daclizumab) that promote expansion of natural killer (NK) cells are associated with clinical amelioration of disease in the context of multiple sclerosis and associated mouse models. The clinical benefits are putatively attributable to an enhanced capacity of NK cells to kill activated pathogenic T cells. Whether a parallel approach will also be effective in systemic lupus erythematosus (lupus), a multi-organ autoimmune disease driven by aberrant responses of self-reactive T and B cells, is unclear.

Methods: In the present study, the authors assess the therapeutic impact of IL-2- and IL-15-based strategies for expanding NK cells on measures of lupus-like disease in a mouse model.

Results: Unexpectedly, cytokine-mediated expansion of cytotoxic lymphocytes aggravated immunological measures of lupus-like disease. Depletion studies revealed that the negative effects of these cytokine-based regimens can largely be attributed to expansion of CD8 T cells rather than NK cells.

Conclusions: These results provoke caution in the use of cytokine-based therapeutics to treat co-morbid cancers in patients with lupus and highlight the need for new methods to selectively expand NK cells to further assess their clinical value in autoimmune disease.

© 2020 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.

Introduction

The Centers for Disease Control and Prevention estimates that 161,000 Americans, most of whom are ethnic minorities and women of child-bearing age, suffer the debilitating consequences of systemic lupus erythematosus (lupus). Lupus is an autoimmune disease characterized by the rampant production of autoantibodies that drive widespread organ damage [1]. As a result, lupus is the fifth leading cause of death for African American and Hispanic women between 15 and 24 years of age [2]. There is no cure for lupus, and therapy is limited mostly to immunosuppressive drugs. Among numerous side effects, these treatments also broadly dampen immune responses, causing impaired wound healing and an increased susceptibility to dangerous infections.

There is a growing focus on developing immunomodulatory therapies that more selectively constrain pathogenic autoreactive lymphocytes in patients with lupus, thereby obviating the need for potentially harmful non-selective suppression of the immune system.

Multiple lines of evidence in patients with lupus and in mouse models of lupus-like disease point to dysregulation of follicular helper T-cell (T_{FH}) and germinal center (GC) B-cell responses as a key driver of disease pathogenesis [3–5]. The resulting aberrant GC responses facilitate development of autoantibody-secreting plasmablasts that contribute to harmful inflammation and pathogenic deposition of immune complexes in affected organs, including the kidney [1]. Although clinical strategies to deplete T_{FH} are presently lacking, broad depletion of B cells [6] and neutralization of the B-cell activating factor [7] show promise for ameliorating lupus disease. These results suggest that other immunotherapeutic strategies that target T_{FH} and B cells may be able to effectively alleviate lupus disease.

The authors' previous work revealed that natural killer (NK) cells exhibit potent immunosuppressive capacity that limits T_{FH} and GC

* Correspondence: Stephen N. Waggoner, PhD, Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, MLC 15012, Cincinnati, Ohio 45229-3039, USA.

E-mail address: stephen.waggoner@cchmc.org (S.N. Waggoner).

responses resulting from infection or vaccination [8,9]. This activity involves perforin-dependent lysis of a fraction of activated CD4 T cells by NK cells, resulting in reduced antiviral CD8 T-cell and humoral immune responses [8–10]. Unfortunately, the frequency and function of circulating NK cells are markedly reduced in patients with lupus [11–15], particularly during disease flares [16,17]. Likewise, NK cell frequencies are reduced in mouse models of lupus-like disease, including Fas-mutant *lpr* mice [18]. Of note, antibody-mediated depletion of NK cells in these mice accelerates disease, whereas adoptive transfer of NK cells delays disease onset [18]. These data suggest that an inherent or acquired NK cell numeric and functional deficiency may contribute to the pathogenesis of lupus. Moreover, the reduced NK cell pool in the context of lupus, coupled with the potent immunoregulatory function of these cells, raises the specter of therapeutically expanding NK cells to alleviate lupus disease.

Several methods currently exist to semi-selectively expand endogenous NK cell populations *in vivo* [19–22]. These reagents are often based on the NK cell stimulating activities of the cytokines IL-2 and IL-15 [23,24]. Of note, both IL-2 and IL-15 engage NK cells via IL-2 beta receptor (IL-2R β , or CD122), which is also expressed on activated T and NK T cells [25]. Therefore, targeting of IL-2 to IL-2R β via daclizumab (anti-IL-2R α antibody) or IL-2/anti-IL-2 (clone S4B6) antibody complexes (IL-2C) results in marked expansion of the NK cell and CD8 T-cell compartments in mice and humans [23,26]. Daclizumab-mediated expansion of immunoregulatory NK cells in multiple sclerosis patients is linked to clinical lessening of disease [26,27], whereas IL-2C treatment reduces disease measures in the MRL/*lpr* mouse model of lupus [28]. Likewise, lupus-like disease in the B6 $\times$ DBA/2 F1 mouse model is alleviated by therapeutic administration of IL-2C [29]. By contrast, pre-treatment with IL-2C prior to disease initiation results in worse disease [29]. The potential contributions of both NK cells and CD8 T cells in these disparate models complicate interpretation of any potential clinical benefits of IL-2C in human lupus. Moreover, distinct functional consequences of IL-15- versus IL-2-mediated expansion of NK cells in infection models [30] suggest that IL-15 superagonist compounds like N-803 (previously known as ALT-803 [31]) may provoke greater immunoregulatory functions in expanded NK cells.

In the present study, the authors compare the prophylactic and therapeutic effects of both IL-2C- and N-803-induced expansion of NK and CD8 T cells in a mouse model of lupus-like disease. In this chronic graft-versus-host disease (cGVHD) model [32,33], CD4 T cells from B6(C)-H2-Ab1^{bm12}/KhEgJ (bm12) donor mice undergo alloactivation following transfer into C57BL/6 mice due to three amino acid mismatches between their major histocompatibility complex class II I-A^b molecules. The resulting cGVHD provokes numerous immunological manifestations resembling lupus, including robust T_H and GC B-cell responses, elaboration of antinuclear antibody (ANA) and development of glomerulonephritis. Surprisingly, both IL-2C and N-803 exacerbated immunological measures of disease in this mouse model. CD8 T cells, but not NK cells, were linked to immune enhancement in this disease model following cytokine treatment.

Methods

Mice

C57BL/6 and CD45.1⁺ (B6.SJL-*Ptprca*^{pc}/BoyJ) breeder pairs and experimental recipient mice were obtained from The Jackson Laboratory (Bar Harbor, ME). CD45.1⁺ B6(C)-H2-Ab1^{bm12}/KhEgJ (bm12) mice were a kind gift from Dr Edith Janssen. Male and female mice between eight and 20 weeks of age were used in experiments. All mice were maintained under specific pathogen-free conditions in accordance with guidelines from the Association for Assessment and Accreditation of Laboratory Animal Care International. Experiments were performed in accordance with ethical guidelines approved by the Institutional Animal Use and Care Committee of Cincinnati Children's Hospital Medical Center.

Bm12 cell transfer and tissue harvest

Spleens were harvested from B6(C)-H2-Ab1^{bm12}/KhEgJ (bm12) donor mice and passed through 70- μ m nylon strainers to obtain single-cell suspensions. Following enumeration using 3% acetic acid with Methylene Blue (STEMCELL Technologies Inc, Vancouver, Canada), splenocytes were resuspended in phosphate-buffered saline (PBS) and 40–60 million cells were injected either intraperitoneally or intravenously (via retro-orbital injection under isoflurane anesthesia) into each recipient C57BL/6 mouse. This range of donor cells falls above the necessary minimum dose of 30 million splenocytes previously determined by our colleagues and noted elsewhere [32]. Although early experiments utilized an intraperitoneal graft injection that is traditional to the disease model, later experiments used intravenous delivery because of an observed enhanced consistency of engraftment that did not significantly affect downstream disease measures (data not shown).

Donor and recipient mice were age-matched. Female-derived grafts were injected into female or male hosts, or male-derived grafts into male hosts, but not male-derived grafts into female hosts, so as to avoid Y chromosome-mediated rejection. When necessary, whole blood was obtained via laceration of the tail vein and collected into either ethylenediaminetetraacetic acid or SST Microtainer tubes (BD Biosciences, San Jose, CA). Prior to staining for flow cytometry, whole blood from ethylenediaminetetraacetic acid tubes was subjected to red blood cell lysis via ammonium-chloride-potassium lysing buffer (Thermo Fisher Scientific, Waltham, MA). Following euthanasia, mouse spleens were weighed and processed into single-cell suspensions (as discussed earlier), splenic red blood cells were lysed (as discussed earlier) and remaining splenocytes were enumerated using either Trypan Blue exclusion or 3% acetic acid with Methylene Blue prior to staining for flow cytometry. Whole blood was collected through the inferior vena cava and serum was isolated using SST Microtainer tubes. Because of unknown factors in the authors' vivarium, immune perturbation and ANA production did not lead to measurable kidney damage or proteinuria in any of the mice assayed in this article.

Targeted cytokine treatment

For each mouse, 1 μ g of recombinant murine IL-2 (PeproTech, Rocky Hill, NJ) was combined with 10 μ g anti-mouse IL-2 (clone S4B6; Bio X Cell, Lebanon, NH) in 200 μ L Hank's Balanced Salt Solution (HBSS), then incubated overnight at 4°C while mixing. For each control mouse, 1 μ g of recombinant murine IL-2 was incubated overnight with 10 μ g rat IgG2a (Bio X Cell, Lebanon, NH) in 200 μ L HBSS. As a pre-disease treatment, each mixture was intraperitoneally injected every other day for a total of three injections, after which a bm12 splenocyte graft was injected the following day (see earlier discussion). As a post-disease treatment, injections were administered once daily for 3 days beginning 1 month after graft injection [29].

Experimental mice received 200 μ g/kg of N-803 (provided via collaboration with Altor BioScience, now part of NantWorks LLC, Los Angeles, CA) in PBS injected subcutaneously, whereas control mice received a molar equivalent of recombinant human IL-15 (PeproTech, Rocky Hill, NJ) in PBS. As a pre-disease treatment, two injections were administered once every other day, finishing 1 day prior to bm12 graft injection. As a post-disease treatment, injections were administered once weekly over the course of 3 months, beginning 1 week after bm12 graft injection, for a total of 11 treatments.

Administration of cell-depleting antibodies

For NK cell, CD8 T-cell or mock depletion, mice were intraperitoneally injected once with 25 μ g *InVivo*MAB anti-mouse NK1.1 (clone PK136; Bio X Cell, Lebanon, NH) [10], 100 μ g *InVivo*MAB anti-mouse CD8 α (clone YTS169.4; Bio X Cell, Lebanon, NH) or 25 μ g *InVivo*MAB

mouse IgG2a isotype control (clone BE0085; Bio X Cell, Lebanon, NH) in HBSS, respectively. Antibodies were administered 1 day prior to the first treatment with either IL-2/ α IL-2 complexes or N-803 or their respective controls.

Enzyme-linked immunosorbent assays

Mouse serum or plasma was assessed via the IgG (total) mouse enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's directions using 96-well Nunc MaxiSorp plates (Thermo Fisher Scientific, Waltham, MA), with samples diluted 1:20 000 to 1:40 000. Serum or plasma was assessed for ANA using the mouse ANA total Ig ELISA kit (Alpha Diagnostic International, San Antonio, TX) according to the manufacturer's directions, with samples diluted 1:50. Total IgG and ANA ELISA plates were read using a GloMax Discover microplate reader (Promega, Madison, WI) on the absorbance setting at 450 nm.

Flow cytometry

Fluorescently conjugated antibodies were obtained from BioLegend (San Diego, CA), eBioscience (San Diego, CA), Invitrogen (Carlsbad, CA) or BD Biosciences (San Jose, CA). For surface staining, cells were resuspended at a concentration of $1-2 \times 10^6$ /mL in 50–100 μ L of cold HBSS containing 5% heat-inactivated fetal bovine serum (Gibco, Carlsbad, CA), 100 U/mL penicillin and 100 μ g/mL streptomycin (fluorescence-activated cell sorting [FACS] buffer). Fluorescently conjugated antibodies were added at the manufacturer's recommended concentration. Cells were incubated at 4°C for 20 min, then washed twice with FACS buffer and analyzed either fresh (same-day) or fixed using 100 μ L Cytofix (BD Biosciences, San Jose, CA) for 20 min at 4°C. All fixed cells were washed twice with FACS buffer to remove fixative and kept at 4°C in FACS buffer until analysis (1–3 days later). Acquisition of stained cells was

performed using an LSRFortessa or LSR II cytometer with FACSDiva software (BD Biosciences, San Jose, CA).

Statistical analyses

Flow cytometric analysis was performed using FlowJo v.10 software. Compensation was performed using single-color-stained cells and/or UltraComp eBeads (Thermo Fisher Scientific, Carlsbad, CA), whereas Zombie dye single-color controls were made using cells pre-heated on a heat block at 70°C for 10 min. All electronic gating was performed downstream of a forward scatter area by forward scatter height “single” gate. ELISA standard curves were generated using the linear regression function in GraphPad Prism (San Diego, CA), during which analyte concentrations were interpolated based on optical density values, then calculated based on dilution factor.

Statistical analysis was performed using GraphPad Prism 8. Normal distribution of data was assessed by Kolmogorov–Smirnov test. Significant differences between two datasets exhibiting normal distribution were assessed by unpaired two-tailed Student's *t*-test, whereas non-normally distributed datasets were compared using Mann–Whitney U test. Comparisons among multiple groups were made via Kruskal–Wallis test with Dunn's multiple comparison testing of group means. Nonparametric Spearman correlation was used to assess relationships between independent measurements.

Results

The bm12 cGVHD model is associated with contraction of the NK cell compartment

Injection of splenocytes from CD45.1⁺ bm12 mice (graft) into CD45.2⁺ C57BL/6 recipient (host) mice resulted in marked

Figure 1. Cytokine-mediated reversal of NK cell attrition associated with bm12 lupus model. C57BL/6 mice received a graft of CD45.1⁺ (control) or CD45.1⁺ bm12 splenocytes and were evaluated 2 weeks later. (A) Spleen masses, spleen cellularities, donor CD45.1⁺ CXCR5⁺ PD-1⁺ CD4⁺ T_H counts, host CD19⁺ Fas⁺ GL7⁺ GC B cell counts and host CD19⁺ CD138⁺ plasmablast counts are displayed ($n = 6$ mice per group). (B) Total splenic NK cells (CD3⁺ NK1.1⁺ NKp46⁺) in control- and bm12-engrafted mice ($n = 12-15$ per group) that were pre-treated with either IL-2C or N-803 as described in the methods section. (C) Cell surface phenotype of NK cells in control- and bm12-engrafted mice ($n = 3-4$ per group) determined by flow cytometric assessment of receptor staining intensity. Results are representative of two or more experimental replicates. (Color version of figure is available online).

splenomegaly characterized by activation and expansion of graft PD1⁺ CXCR5⁺ CD4⁺ T_{FH} cells, host Fas⁺ GL7⁺ CD19⁺ GC B cells and host CD138⁺ CD19⁺ plasmablasts relative to C57BL/6 receiving a control graft of B6J splenocytes (Figure 1A). Despite the increase in splenocyte count during this cGVHD response, the numbers of host CD3⁺ NK1.1⁺ NKp46⁺ NK cells were 60% reduced ($P = 0.0002$) in the spleen (Figure 1B). This contraction of the NK cell compartment is consistent with that observed in other mouse models of lupus-like disease [18] as well as in patients with lupus [11–15]. In addition to quantitative reductions, host CD3⁺ NK1.1⁺ NKp46⁺ splenic NK cells from bm12-engrafted mice exhibited higher surface expression of CD27 (*Tnfrsf7*), NKG2A (*Klrc1*), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/*Tnfrsf10*) and CD11c (*Itgax*) than that seen in mice injected with a CD45.1⁺ control graft (Figure 1C). This phenotype (CD27⁺, NKG2A⁺, TRAIL⁺) is consistent with more immature NK cells [34], whereas the increased expression of CD11c is characteristic of an atypical, pro-inflammatory NK cell subset observed in patients with lupus and certain mouse models of lupus-like disease [35–37].

Disease-associated attrition of NK cells can be reversed with targeted cytokine treatment

Injections of IL-2C (IL-2 complexed with S4B6 anti-IL-2 antibody) or the IL-15 superagonist N-803 into C57BL/6 mice resulted in expansion of the NK cell and CD8 T-cell compartments, whereas Foxp3⁺ CD4⁺ T regulatory cell proportions remained relatively unchanged [38,39]. To determine if NK cell attrition in the bm12 model could be averted via cytokine-mediated expansion of the NK cell compartment, the authors treated C57BL/6 mice with IL-2C three times over a span of 6 days prior to initiation of the disease model. Pre-treatment with IL-2C before injection of bm12 cells resulted in a >6-fold increase in host splenic NK cell frequencies relative to control-treated (IL-2 and rat IgG2a) mice receiving a bm12 graft (Figure 1B). Likewise, pre-treatment with N-803 promoted a >5-fold increase in the frequency of host splenic NK cells relative to untreated bm12-engrafted mice. Of note, NK cell frequencies in IL-2C- or N-803-treated mice were >2-fold greater than that seen in control mice given a non-disease-inducing graft of CD45.1⁺ splenocytes (Figure 1B). N-803 pre-treatment further increased upregulation of CD27 (IL-15, 1945 ± 404 mean fluorescence intensity [MFI], N-803, 3401 ± 656 MFI, $n = 4$ per group, $P = 0.004$) and NKG2A (IL-15, 218 ± 44 MFI, N-803, 1120 ± 88

MFI, $n = 4$ per group, $P = 0.002$) on NK cells after bm12 cell transfer but had no added effect on expression of TRAIL or CD11c (data not shown). Similar observations were seen with IL-2C (data not shown). Thus, cytokine-mediated expansion of NK cells prior to bm12 cell transfer can prevent or even reverse model-associated attrition of NK cells.

IL-2C pre-treatment transiently exacerbates cGVHD

The diminished number of potentially immunoregulatory NK cells [8–10,26,40–51] in the bm12 model of disease (Figure 1B) may contribute to dysregulated responses of T and B cells, leading to autoimmune disease. Accordingly, the marked expansion and maintenance of a high number of NK cells after IL-2C pre-treatment (Figures 1B, 2A) should result in diminished measures of cGVHD and lupus-like disease. In contrast to expectations, the number of donor T_{FH}, host GC B cells and plasmablasts in the spleen of IL-2C-treated, bm12-engrafted C57BL/6 mice 2 weeks after disease initiation was elevated relative to mice treated with IL-2 and non-complexed irrelevant IgG2a (Figure 2A). CD8 T-cell counts were also elevated at the 2-week time point (control, $6.4 \pm 1.9 \times 10^6$, IL-2C, $10.4 \pm 2.6 \times 10^6$, $n = 6–7$, $P = 0.01$). Total serum IgG levels were elevated relative to baseline (as expected at this time point) but to similar levels in IL-2C-treated and untreated bm12-recipient mice (Figure 2A). Neither the expansion of NK cells and host CD45.2⁺ CD8 T cells (control, $15.1 \pm 2.2 \times 10^6$, IL-2C, $22.2 \pm 11.1 \times 10^6$, $n = 6–7$, $P = 0.1$) nor the enhanced immunological measures of disease were sustained at the 3-month time point, whereas IL-2/S4B6 pre-treated and control-treated mice exhibited similar numbers of donor T_{FH}, host GC B cells and plasmablasts (Figure 2B). Comparable titers of total IgG (not shown) and ANA, which became measurable at this time point, were also observed in sera of IL-2/S4B6 pre-treated mice relative to controls (Figure 2B). Thus, increased immunological cGVHD measurements at the 2-week time point in IL-2/S4B6 pre-treated mice (Figure 2A) were not associated with measurable amplification of later measures (Figure 2B) of immune disease in this model.

Therapeutic application of IL-2C exacerbates lupus-like disease in mice

To assess whether therapeutic cytokine-mediated expansion of NK cells could alleviate established lupus-like disease, control and

Figure 2. IL-2C pre-treatment transiently exacerbates cGVHD. C57BL/6 mice were given three injections of IL-2C (IL-2/S4B6) or IL-2/IgG2a (control) over a span of 6 days prior to infusion of bm12 splenocytes. The number of donor CD45.1⁺ CXCR5⁺ PD-1⁺ CD4⁺ T_{FH}, host CD19⁺ Fas⁺ GL7⁺ GC B cells, CD19⁺ CD138⁺ plasmablasts and NK1.1⁺ NKp46⁺ CD3⁺ NK cells in recipient spleens ($n = 7–8$ per group) was evaluated by flow cytometry 2 weeks (A) or 3 months (B) after disease initiation. Sera IgG and ANA titers were evaluated by ELISA at 2-week and 3-month time points, respectively. Results are representative of at least two experimental replicates performed for each measurement. (Color version of figure is available online).

Figure 3. Therapeutic application of IL-2C aggravates bm12-induced disease. C57BL/6 mice were administered bm12 splenocytes 1 month prior to application of three daily injections of IL-2C (IL-2/S4B6) or IL-2/IgG2a (control). The numbers of host splenic CD19⁺ Fas⁺ GL7⁺ GC B cells and CD19⁺ CD138⁺ plasmablasts as well as sera titers of IgG and ANA were evaluated ($n = 4-7$ mice per group) 2 months after IL-2C therapy (third month of disease). Results are representative of at least two experimental replicates. (Color version of figure is available online).

bm12-recipient mice were administered daily therapeutic regimens of IL-2C for 3 consecutive days starting 1 month after disease initiation, an approach that parallels a prior study using this complex in a similar disease model [29]. Two months after therapy initiation, IL-2C-treated mice exhibited increased host splenic plasmablast counts and elevated sera ANA titers relative to control-treated mice (Figure 3). Non-significant trends for elevations in host GC B-cell

counts and total sera IgG expression levels were also observed. Thus, similar to pre-treatment, therapeutic application of IL-2C exacerbated measures of disease in this model.

N-803 pre-treatment transiently exacerbates cGVHD

Since IL-15-based expansion can more robustly trigger accumulation of NK cells with greater immunoregulatory capacity than is seen with IL-2C-mediated expansion [30], especially when using the novel IL-15 superagonist N-803 [52], the authors tested the hypothesis that N-803 pre-treatment would reduce disease measures in the bm12 model. Unfortunately, donor T_{FH}, host GC B-cell, CD8 T-cell and plasmablast counts were also elevated in diseased mice pre-treated with N-803 relative to control mice treated with molar-equivalent IL-15 (Figure 4A). There was also a non-statistically significant trend toward increased sera IgG titers at 2 weeks in N-803 pre-treated mice (Figure 4A). The measured increases in T_{FH}, GC B cells, plasmablasts and CD8 T cells were short-lived, as analysis 3 months post-disease initiation revealed similar numbers of these cells and comparable ANA titers in N-803 pre-treated mice relative to control mice (Figure 4B). Elevated NK cell frequencies with N-803 treatment at 2 weeks (Figure 1B) also returned to baseline (IL-15, $3.1 \pm 2.3 \times 10^6$, N-803, $2.6 \pm 1.5 \times 10^6$, $n = 8-9$, $P = 0.7$).

Therapeutic application of N-803 exacerbates immune responses

To assess whether N-803 treatment could alleviate established lupus-like disease, a clinically relevant regimen [53,54] of weekly N-803 or control IL-15 injections was initiated 1 week after bm12 splenocyte infusion and continued for up to 11 weeks. Early (1–2 months) after therapy initiation, there was a trend for increased donor (CD45.1⁺) T_{FH} cell as well as host, plasmablast, GC B-cell and CD8 T-cell frequencies in mice treated with N-803 therapeutically relative to control-treated mice (Figure 5A). Because of pandemic interruptions, replicate experiments spanned from 1 to 5 months post-treatment initiation. Collective analysis of treated and control mice revealed that the number of splenic CD8 T cells across this time span showed a positive correlation with the number of both splenic plasmablasts and donor T_{FH} (Figure 5B). By contrast, NK cell

Figure 4. N-803 pre-treatment transiently exacerbates bm12-induced disease. C57BL/6 mice were given two injections of 200 μ g/kg N-803 or IL-15 (control) over a span of 4 days prior to infusion of bm12 lymphocytes. Splenic CD45.1⁺ CXCR5⁺ PD-1⁺ CD4⁺ T_{FH}, host CD19⁺ Fas⁺ GL7⁺ GC B cells, CD19⁺ CD138⁺ plasmablasts and host CD45.2⁺ CD3⁺ CD8⁺ T cells as well as sera IgG and ANA titers were assessed 2 weeks ($n = 8$ per group) (A) or 3 months ($n = 8-9$ per group) (B) after disease initiation. ANA was only assessed in mice from whom a sufficient quantity of blood was obtained. Similar results were obtained in two independent experimental replicates (A). Replicate experiments were pooled (B). (Color version of figure is available online).

Figure 5. N-803 therapy augments bm12-induced disease measures. C57BL/6 mice were administered bm12 splenocytes 1 week prior to application of onset of weekly injections of 200 $\mu\text{g/kg}$ N-803 or IL-15 (control). (A) The number of donor CD45.1⁺ CXCR5⁺ PD-1⁺ CD4⁺ T_H cells and CD19⁺ Fas⁺ GL7⁺ GC B cells, CD19⁺ CD138⁺ plasmablasts, host CD45.2⁺ CD3⁺ CD8⁺ T cells and Nkp46⁺ NK1.1 CD3⁺ NK cells in spleen was assessed in groups of mice ($n = 7-8$ per group) at 1–2 months post-disease initiation. Spearman correlation analysis in mice assessed across a 5-month time span showing association between CD8 T cells and plasmablast or T_H frequency (B) as well as association between NK cell and T_H frequencies (C). Results are pooled from replicate experiments.

frequencies exhibited a weak negative correlation with donor T_H frequencies (Figure 5C). Therapeutic N-803 treatment was also associated with non-significant ($P > 0.1$) increases in sera ANA titers 1–2 months (control, 4.5 ± 1.8 kU/mL, N-803, 6.4 ± 2.8 kU/mL, $n = 6-7$) and 3–5 months (control, 4.4 ± 1.6 kU/mL, N-803, 5.6 ± 2.5 kU/mL, $n = 10-11$) after treatment initiation. Collectively, these data suggest that N-803 therapy after disease initiation mildly exacerbated immune measures of disease in this model and that this phenomenon may be associated with an expanded CD8 T-cell compartment.

CD8 T cells, but not NK cells, contribute to N-803-mediated enhanced B-cell responses

Cytokine pre-treatment-induced expansion of CD8 T cells and NK cells was temporally associated with enhanced immunological measures of disease in this mouse model (Figures 2, 4), yet only CD8 T-cell frequencies showed positive correlations with these parameters with therapeutic cytokine expansion (Figure 5). Therefore, the authors sought to evaluate the dueling contribution of NK cells and CD8 T cells to enhanced disease measures by depleting each of these cell types with anti-NK1.1 and anti-CD8 α antibodies, respectively. Thereafter, depleted and non-depleted mice were pre-treated with N-803 for 1 week prior to engraftment of bm12 splenocytes. Both N-803- and IL-2C-stimulated expansions of CD8 T and NK cells were ablated by depletion of CD8 T cells (Figure 6A,D) or NK cells (Figure 6B,E), respectively, without affecting the opposing population of cells. Importantly, host GC B-cell responses were increased following N-803 pre-treatment of bm12-engrafted mice in non-depleted control mice ($P = 0.002$) and in mice depleted of NK cells ($P = 0.003$) prior to N-803 administration (Figure 6C). However, this increase was ameliorated ($P = 1.0$) by CD8 T-cell depletion prior to N-803 therapy. In a similar fashion, CD8 T-cell but not NK cell depletion resulted in normalization of GC B-cell responses after IL-2C treatment (Figure 6F). Thus, cytokine-induced increases in CD8 T-cell frequencies in the bm12 lupus-like cGVHD model are associated with enhanced immunological measures of disease.

Discussion

The investigation herein sought to determine whether IL-2C- or N-803-mediated expansion of NK cells would alleviate lupus-like disease features in the bm12-based cGVHD mouse model. Unexpectedly, therapeutic and prophylactic administration of these cytokine-based therapeutics at least transiently enhanced disease measures. Through depletion studies, CD8 T cells were implicated in the disease-aggravating activity of these cytokine-based therapeutics. These results suggest that activation and expansion of CD8 T cells may be unfavorable in the context of lupus, which is consistent with the correlation between elevated CD8 T-cell frequencies and poor disease prognosis in patients with lupus [55]. The authors' findings represent pertinent discoveries regarding the dynamics between NK cells, CD8 T cells and systemic autoimmune disease in mice.

Similar to the paucity of circulating NK cells in patients with lupus and reduced numbers of NK cells in other mouse models of lupus-like disease [11–16,37,56,57], the authors observed a marked contraction of the NK cell compartment in mice subjected to the bm12 cGVHD model. Though the cause of this contraction remains undefined, the authors found that prophylactic treatment of diseased mice with either IL-2C or N-803 could counteract NK cell loss and even promote expansion of the NK cell pool. Coupled with experiments detailing IL-2-based therapeutics in the MRL/lpr and B6 $\times$ DBA mouse models [28,29], these data support the conclusion that therapeutic expansion of NK cells is possible in the context of lupus-like disease.

Unfortunately, application of IL-2C or N-803 to the bm12 cGVHD model of lupus at least transiently exacerbated disease. In both treatment approaches, the expansion of CD8 T cells was implicated in exaggerated bm12 engraftment-induced GC responses, as supported by CD8 depletion studies. Though the anti-CD8 α antibody used to deplete CD8 T cells can also deplete CD8 α ⁺ dendritic cells [58], dendritic cells are not known to respond to N-803 [53]. Dendritic cells are thus unlikely to be a confounding driver of N-803-exacerbated disease that can be reversed with CD8 α -depleting antibody. However, as N-803 can promote secretion of interferon gamma (IFN- γ) from CD8 T cells [31,39,59,60], and IFN- γ can cause pathologic accumulation of T_H cells and GCs [61–63],

Figure 6. Contribution of CD8 T cells to cytokine augmentation of immune disease. C57BL/6 mice (n = 4–13 per group) were treated with IgG2a isotype control, 25 μ g anti-NK1.1 antibody (Δ NK) or 100 μ g anti-CD8 α antibody (Δ CD8) 1 day prior to N-803 (A–C), IL-2C (D–F) or appropriate control treatments as described in the methods section. CD3⁺ CD8⁺ T-cell (A,D), CD3⁺ NK1.1⁺ NKp46⁺ NK cell (B,E) and CD19⁺ Fas⁺ GL7⁺ GC B-cell (C,F) counts in spleen were determined by flow cytometry 2 weeks after bm12 disease initiation in groups of mice (n = 4–13 per group). Statistically significant changes over time points or between treatment groups determined by Kruskal–Wallis test with Dunn's multiple comparison testing. Results are pooled from two to three independent experiments. (Color version of figure is available online).

the authors speculate that excess IFN- γ production after N-803 or IL-2C therapy may provoke worse disease outcomes, a possibility the authors will continue to explore. Regardless of the mechanism by which CD8 T cells may aggravate disease measures in this model, it is interesting to note that the authors' results contrast with those obtained following therapeutic application of IL-2C to the B6 $\times$ DBA/2 F1 cGVHD mouse model of lupus-like disease [29], in which IL-2C-stimulated CD8 T cells ameliorated disease. This dichotomy is likely explained by the role of additional class I major histocompatibility complex mismatches in the B6 $\times$ DBA/2 F1 model that are not present in the bm12 model. In the B6 $\times$ DBA/2 F1 system, IL-2C enhancement of CD8 T cells leads to improved rejection of class I-mismatched cells, thereby curtailing the cGVHD response driving lupus-like disease. A similar elimination of pathogenic cells may drive the reduction in disease observed after IL-2C therapy of lupus-like disease in MRL/lpr mice.

Although evidence for beneficial functions of NK cells in lupus remains scarce, the authors' data suggest that specific expansion of NK cells (in the context of CD8 T-cell depletion) is not necessarily detrimental to disease progression. The potential for increased clinical safety of NK cell-based versus T-cell-based immunotherapy strategies has already been established in the context of chimeric antigen receptor cellular therapy of cancer [64]. Since no mouse model of lupus-like disease accurately reflects all of the parameters driving human lupus, these studies collectively suggest that cytokine-mediated expansion of effector lymphocytes may still hold promise in the clinic if the dueling roles of NK cells and CD8 T cells in lupus-like disease can be better delineated. The advancement and further testing of NK cell expansion for autoimmune disease will likely require development of reagents that specifically target NK cells and an improved understanding of the factors driving specific subsets of immunoregulatory NK cells.

Collectively, the authors' data suggest that treatment of lupus with immunotherapeutics that selectively expand endogenous CD8 T and NK

cells should be approached with caution and may not achieve the therapeutic effect of similar agents that has been observed in multiple sclerosis. Moreover, the increased risk of hematologic malignancy in patients with lupus [65] may complicate clinical application of N-803 or other anti-tumor therapeutics with the potential to aggravate autoimmune sequelae in these patients. By contrast, NK cells are potent anti-tumor effector cells, and selective expansion of these cells without concurrent autoimmune exacerbation by T cells may provide clinically valuable anti-leukemic effects even if these NK cells are unable to alleviate underlying elements of lupus-like disease.

Funding

Investigators on this project were supported by National Institutes of Health grants DA038017, AI148080, AR073228, AI145304 (SNW), T32GM063483, T32AI118697 (SDR and AA), AR071651 and AR076316 (HIB). Additional support was provided to SNW and HIB by Cincinnati Children's Research Foundation, the Cincinnati Center for Pediatric Genomics and the Dr Ralph and Marian Falk Medical Research Trust. SDR was also supported by a Gina Finzi Memorial Student Fellowship from the Lupus Foundation. DEO is supported by an American Heart Association Fellowship and the Arnold Strauss Fellowship. AA is supported by the Albert Ryan Fellowship. The Cincinnati Children's Flow Cytometry Core is supported by National Institutes of Health grants AR047363, AR070549, DK078392, DK090971, S10OD025045 and S10OD023410. N-803 and guidance in use of this drug were kindly provided by the team at ImmunBio (formerly known as Altor BioScience).

Declaration of Competing Interest

The authors have no commercial, proprietary or financial interest in the products or companies described in this article.

Author Contributions

Conception and design of the study: SNW and SDR. Acquisition of data: SDR, DK, HC, DEO, AA, and HS. Analysis and interpretation of data: SDR, DK, HC, DEO, AA, HS, and SNW. Drafting or revising the manuscript: SDR, DK, HC, DEO, AA, HS, HIB, and SNW. All authors have approved the final article.

Acknowledgments

The authors thank J. Klarquist and E. Janssen for expertise and for generating the bm12/CD45.1 mouse line that was used for the disease model. The authors also thank Q. Ma, P. Devarajan and W. Shao for assistance in evaluating lupus-like disease.

References

- [1] Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. *Nature reviews. Rheumatology* 2016;12(12):716–30.
- [2] Yen EY, Singh RR, Report Brief. Lupus—An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000–2015. *Arthritis & rheumatology* 2018;70(8):1251–5.
- [3] Blanco P, Ueno H, Schmitt N. T follicular helper (T_{fh}) cells in lupus: activation and involvement in SLE pathogenesis. *European journal of immunology* 2016;46(2):281–90.
- [4] Kim SJ, Lee K, Diamond B. Follicular Helper T Cells in Systemic Lupus Erythematosus. *Frontiers in immunology* 2018;9:1793.
- [5] Jiang SH, Shen N, Vinuesa CG. Posttranscriptional T cell gene regulation to limit T_{fh} cells and autoimmunity. *Current opinion in immunology* 2015;37:21–7.
- [6] Furtado J, Isenberg DA. B cell elimination in systemic lupus erythematosus. *Clinical immunology* 2013;146(2):90–103.
- [7] Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, Group B-S. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet* 2011;377(9767):721–31.
- [8] Rydzynski CE, Cranert SA, Zhou JQ, Xu H, Kleinstein SH, Singh H, Waggoner SN. Affinity maturation is impaired by natural killer cell suppression of germinal centers. *Cell reports* 2018;24(13):3367–3373.e4.
- [9] Rydzynski C, Daniels KA, Karnele EP, Brooks TR, Mahl SE, Moran MT, Li C, Sutiwasak R, Welsh RM, Waggoner SN. Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells. *Nature communications* 2015;6:6375.
- [10] Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. *Nature* 2012;481(7381):394–8.
- [11] Huang Z, Fu B, Zheng SG, Li X, Sun R, Tian Z, Wei H. Involvement of CD226+ NK cells in immunopathogenesis of systemic lupus erythematosus. *Journal of immunology* 2011;186(6):3421–31.
- [12] Sibbitt Jr. WL, Froelich CJ, Bankhurst AD. Abnormal interferon modulation of natural cytotoxicity in systemic lupus erythematosus. Relation to suppressive serum factors. *Arthritis and rheumatism* 1983;26(12):1452–9.
- [13] Sibbitt Jr. WL, Likar L, Spellman CW, Bankhurst AD. Impaired natural killer cell function in systemic lupus erythematosus. Relationship to interleukin-2 production. *Arthritis and rheumatism* 1983;26(11):1316–20.
- [14] Sibbitt Jr. WL, Mathews PM, Bankhurst AD. Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers. *The Journal of clinical investigation* 1983;71(5):1230–9.
- [15] Katz P, Zaytoun AM, Lee Jr. JH, Panush RS, Longley S. Abnormal natural killer cell activity in systemic lupus erythematosus: an intrinsic defect in the lytic event. *Journal of immunology* 1982;129(5):1966–71.
- [16] Henriques A, Teixeira L, Ines L, Carvalheiro T, Gonçalves A, Martinho A, Pais ML, da Silva JA, Paiva A. NK cells dysfunction in systemic lupus erythematosus: relation to disease activity. *Clinical rheumatology* 2013;32(6):805–13.
- [17] Riccieri V, Spadaro A, Parisi G, Taccari E, Moretti T, Bernardini G, Favaroni M, Strom R. Down-regulation of natural killer cells and of gamma/delta T cells in systemic lupus erythematosus. Does it correlate to autoimmunity and to laboratory indices of disease activity? *Lupus* 2000;9(5):333–7.
- [18] Takeda K, Dennert G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. *The Journal of experimental medicine* 1993;177(1):155–64.
- [19] Dianat-Moghadam H, Rokni M, Marofi F, Panahi Y, Yousefi M. Natural killer cell-based immunotherapy: from transplantation toward targeting cancer stem cells. *J Cell Physiol* 2018;234(1):259–73.
- [20] Chiossone L, Vienne M, Kerdiles YM, Vivier E. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more. *Seminars in immunology* 2017;31:55–63.
- [21] Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. *Nature reviews. Cancer* 2016;16(1):7–19.
- [22] Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. *Nature immunology* 2016;17(9):1025–36.
- [23] Tomala J, Chmelova H, Mrkvan T, Rihova B, Kovar M. *In vivo* expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. *Journal of immunology* 2009;183(8):4904–12.
- [24] Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, Clement D, Goodridge J, Malmberg KJ, Wong HC, Fehniger TA. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. *The Journal of clinical investigation* 2017;127(11):4042–58.
- [25] Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. *Nature reviews. Immunology* 2012;12(3):180–90.
- [26] Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. *Proceedings of the National Academy of Sciences of the United States of America* 2006;103(15):5941–6.
- [27] Jiang W, Chai NR, Maric D, Bielekova B. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. *Journal of immunology* 2011;187(2):781–90.
- [28] Mizui M, Koga T, Lieberman LA, Beltran J, Yoshida N, Johnson MC, Tisch R, Tsokos GC. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. *Journal of immunology* 2014;193(5):2168–77.
- [29] Heiler S, Lotscher J, Kreuzaler M, Rolink J, Rolink A. Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease. *Frontiers in immunology* 2018;9:656.
- [30] Burrack KS, Huggins MA, Taras E, Dougherty P, Henzler CM, Yang R, Alter S, Jeng EK, Wong HC, Felices M, Cichocki F, Miller JS, Hart GT, Johnson AJ, Jameson SC, Hamilton SE. Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells. *Immunity* 2018;48(4):760–772.e4.
- [31] Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC, Kong L, Jeng EK, Han K, Marcus WD, Rubinstein MP, Rhode PR, Wong HC. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. *Cancer research* 2013;73(10):3075–86.
- [32] Klarquist J, Janssen EM. The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice. *Journal of visualized experiments: JoVE* 2015;105:e53319.
- [33] Morris SC, Cheek RL, Cohen PL, Eisenberg RA. Autoantibodies in chronic graft versus host result from cognate T-B interactions. *The Journal of experimental medicine* 1990;171(2):503–17.
- [34] Geiger TL, Sun JC. Development and maturation of natural killer cells. *Current opinion in immunology* 2016;39:82–9.
- [35] Voynova EN, Skinner J, Bolland S. Expansion of an atypical NK cell subset in mouse models of systemic lupus erythematosus. *Journal of immunology* 2015;194(4):1503–13.
- [36] Voynova E, Qi CF, Scott B, Bolland S. Cutting Edge: Induction of Inflammatory Disease by Adoptive Transfer of an Atypical NK Cell Subset. *Journal of immunology* 2015;195(3):806–9.
- [37] Cruz-Gonzalez DJ, Gomez-Martin D, Layseca-Espinosa E, Baranda L, Abud-Mendoza C, Alcocer-Varela J, Gonzalez-Amaro R, Monsivais-Urenda AE. Analysis of the regulatory function of natural killer cells from patients with systemic lupus erythematosus. *Clinical and experimental immunology* 2018;191(3):288–300.
- [38] Hao J, Campagnolo D, Liu R, Piao W, Shi S, Hu B, Xiang R, Zhou Q, Vollmer T, Van Kaer L, La Cava A, Shi FD. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. *Ann Neurol* 2011;69(4):721–34.
- [39] Gaither KA, Little AA, McBride AA, Garcia SR, Brar KK, Zhu Z, Platt A, Zhang F, Meadows GG, Zhang H. The immunomodulatory, antitumor and antimetastatic responses of melanoma-bearing normal and alcoholic mice to sunitinib and ALT-803: a combinatorial treatment approach. *Cancer immunology, immunotherapy: CII* 2016;65(9):1123–34.
- [40] Schuster IS, Wikstrom ME, Brizard G, Coudert JD, Estcourt MJ, Manzur M, O'Reilly LA, Smyth MJ, Trapani JA, Hill GR, Andoniou CE, Degli-Esposti MA. TRAIL+ NK cells control CD4+ T cell responses during chronic viral infection to limit autoimmunity. *Immunity* 2014;41(4):646–56.
- [41] Andrews DM, Estcourt MJ, Andoniou CE, Wikstrom ME, Khong A, Voigt V, Fleming P, Tabarias H, Hill GR, van der Most RG, Scalzo AA, Smyth MJ, Degli-Esposti MA. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. *The Journal of experimental medicine* 2010;207(6):1333–43.
- [42] Cook KD, Kline HC, Whitmire JK. NK cells inhibit humoral immunity by reducing the abundance of CD4+ T follicular helper cells during a chronic virus infection. *Journal of leukocyte biology* 2015;98(2):153–62.
- [43] Cook KD, Waggoner SN, Whitmire JK. NK cells and their ability to modulate T cells during virus infections. *Crit Rev Immunol* 2014;34(5):359–88.
- [44] Crome SQ, Lang PA, Lang KS, Ohashi PS. Natural killer cells regulate diverse T cell responses. *Trends in immunology* 2013;34(7):342–9.
- [45] Xu HC, Huang J, Pandya AA, Lang E, Zhuang Y, Thons C, Timm J, Haussinger D, Colonna M, Cantor H, Lang KS, Lang PA. Lymphocytes Negatively Regulate NK Cell Activity via Qa-1b following Viral Infection. *Cell reports* 2017;21(9):2528–40.
- [46] Xu HC, Grusdat M, Pandya AA, Polz R, Huang J, Sharma P, Deenen R, Kohrer K, Rahbar R, Diefenbach A, Gibbert K, Lohning M, Hocker L, Waibler Z, Haussinger D, Mak TW, Ohashi PS, Lang KS, Lang PA. Type I interferon protects antiviral CD8(+) T cells from NK cell cytotoxicity. *Immunity* 2014;40(6):949–60.

- [47] Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, Recher M, Elford AR, Dhanji S, Shaabani N, Tran CW, Dissanayake D, Rahbar R, Ghazarian M, Brustle A, Fine J, Chen P, Weaver CT, Klose C, Diefenbach A, Haussinger D, Carlyle JR, Kaech SM, Mak TW, Ohashi PS. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8⁺ T-cell immunity. *Proceedings of the National Academy of Sciences of the United States of America* 2012;109(4):1210–5.
- [48] Zamora AE, Aguilar EG, Sungur CM, Khuat LT, Dunai C, Lochhead GR, Du J, Pomeroy C, Blazar BR, Longo DL, Venstrom JM, Baumgarth N, Murphy WJ. Licensing delineates helper and effector NK cell subsets during viral infection. *JCI insight* 2017;2(10):e87032.
- [49] Lu L, Ikizawa K, Hu D, Werneck MB, Wucherpfennig KW, Cantor H. Regulation of activated CD4⁺ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. *Immunity* 2007;26(5):593–604.
- [50] Peppas D, Gill US, Reynolds G, Easom NJ, Pallett LJ, Schurich A, Micco L, Nebbia G, Singh HD, Adams DH, Kennedy PT, Maini MK. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. *The Journal of experimental medicine* 2013;210(1):99–114.
- [51] Bradley T, Peppas D, Pedroza-Pacheco I, Li D, Cain DW, Henao R, Venkat V, Hora B, Chen Y, Vandergrift NA, Overman RG, Edwards RW, Woods CW, Tomaras GD, Ferreri G, Ginsburg GS, Connors M, Cohen MS, Moody MA, Borrow P, Haynes BF. RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. *Cell* 2018;175(2):387–399.e17.
- [52] Han KP, Zhu X, Liu B, Jeng E, Kong L, Yovandich JL, Vyas VV, Marcus WD, Chavallaz PA, Romero CA, Rhode PR, Wong HC. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. *Cytokine* 2011;56(3):804–10.
- [53] Webb GM, Molden J, Busman-Sahay K, Abdulhaqq S, Wu HL, Weber WC, Bateman KB, Reed JS, Northrup M, Maier N, Tanaka S, Gao L, Davey B, Carpenter BL, Axthelm MK, Stanton JJ, Smedley J, Greene JM, Safrit JT, Estes JD, Skinner PJ, Sacha JB. The human IL-15 superagonist N-803 promotes migration of virus-specific CD8⁺ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. *PLoS pathogens* 2020;16(3):e1008339.
- [54] Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Killo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. *Blood* 2018;131(23):2515–27.
- [55] McKinney EF, Lyons PA, Carr EJ, Hollis JL, Jayne DR, Willcocks LC, Koukoulaki M, Brazma A, Jovanovic V, Kemeny DM, Pollard AJ, Macary PA, Chaudhry AN, Smith KG. A CD8⁺ T cell transcription signature predicts prognosis in autoimmune disease. *Nature medicine* 2010;16(5):586–91. 1p following 591.
- [56] Spada R, Rojas JM, Barber DF. Recent findings on the role of natural killer cells in the pathogenesis of systemic lupus erythematosus. *Journal of leukocyte biology* 2015;98(4):479–87.
- [57] Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P, Musset L, Debre P, Amoura Z, Vieillard V. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-gamma production in patients with active disease. *Arthritis and rheumatism* 2011;63(6):1698–706.
- [58] Jung SR, Suprunenko T, Ashhurst TM, King NJC, Hofer MJ, Damage Collateral. What Effect Does Anti-CD4 and Anti-CD8alpha Antibody-Mediated Depletion Have on Leukocyte Populations? *Journal of immunology* 2018;201(7):2176–86.
- [59] Bailey CP, Budak-Alpdogan T, Sauter CT, Panis MM, Buyukgoz C, Jeng EK, Wong HC, Flomenberg N, Alpdogan O. New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity. *Oncotarget* 2017;8(27):44366–78.
- [60] Mathios D, Park CK, Marcus WD, Alter S, Rhode PR, Jeng EK, Wong HC, Pardoll DM, Lim M. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. *Int J Cancer* 2016;138(1):187–94.
- [61] Domeier PP, Chodisetti SB, Soni C, Schell SL, Elias MJ, Wong EB, Cooper TK, Kitamura D, Rahman ZS. IFN-gamma receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity. *The Journal of experimental medicine* 2016;213(5):715–32.
- [62] Lee SK, Silva DG, Martin JL, Pratama A, Hu X, Chang PP, Walters G, Vinuesa CG. Interferon-gamma excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. *Immunity* 2012;37(5):880–92.
- [63] Haas C, Ryffel B, Le Hir M. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. *Journal of immunology* 1997;158(11):5484–91.
- [64] Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. *Cell Stem Cell* 2018;23(2):181–192.e5.
- [65] Choi MY, Flood K, Bernatsky S, Ramsey-Goldman R, Clarke AE. A review on SLE and malignancy. *Best Pract Res Clin Rheumatol* 2017;31(3):373–96.